Medical/Pharmaceuticals
Clicklinks | Sanyou Bio Launches Clicklinks, an AI-Driven Innovation Hub for Original Drug Discovery
SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Sanyou Bio"), today announced the official launch of Clicklinks, an AI-STAL and SAI-DA powered collaborative network designed to support original drug discovery and preclinical development. P...
2026-08-28 22:30
118
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
TSY-110 is positioned to become the first biosimilar alternative to Roche's Kadcyla® (ado-trastuzumab emtansine) in major regulated markets. TAIPEI, Aug. 28, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWSE: 6838), today announced the submission of a Clinical Trial Application (CTA) to E...
2026-08-28 20:03
591
HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
* Memorandum of Understanding establishes a framework for joint development of clinical trial simulation capabilities * The partnership unites global clinical operations excellence with advanced digital twin technology, delivering simulation-first drug development to biotech sponsors navigati...
2026-08-28 20:00
579
Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma
SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization of commercial launch and international expansion for its core products, the company is accelerating...
2026-08-28 19:31
726
InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
NANJING, China, Aug. 28, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selectiv...
2026-08-28 19:00
824
Tigermed Announces 2026 Interim Results
HANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its 2026 interim results (the "Reporting Period"). ...
2026-08-28 17:56
545
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively built its IO2...
2026-08-28 10:44
2014
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
INCHEON, South Korea, Aug. 27, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensional, long-term growth strategy across capacity, portfolio, and geogr...
2026-08-28 06:58
1503
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient...
2026-08-27 22:15
3941
Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced ...
2026-08-27 22:09
1619
Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today an...
2026-08-27 22:04
3523
Neurophet Supplies 'Neurophet AQUA' and 'Neurophet AQUA AD Plus' to Elevate Clinic in the U.S., Expanding Its Presence in the U.S. Brain Disorders Market
* Provides solutions for analyzing brain atrophy and white matter hyperintensities, as well as monitoring side effects associated with Alzheimer's disease treatments * Secures a key reference site at a U.S. medical institution specializing in neurological disorders, accelerating product adopt...
2026-08-27 21:00
1876
Neopharma Technologies Achieves ISO/IEC 42001:2023 AI Management System Certification for NEOVAULT® Global Diagnostics Platform
Certification strengthens the governance framework behind NEOVAULT® as Neopharma expands from Fit-for-Duty into broader human health diagnostics NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Neopharma Technologies Ltd ("Neopharma") today announced that it has achieved ISO/IEC 42001:2023 certification ...
2026-08-27 20:20
1132
Nature Biotechnology | Aureka Wins the Global Blinded AI Antibody Benchmark: AI Design Surpasses the Best Experimental Result
SHANGHAI and LAGUNA HILLS, Calif., Aug. 26, 2026 /PRNewswire/ -- The complete
results of AIntibody, the first international AI antibody design competition,
have now been formally published inNature Biotechnology.
2026-08-27 08:00
2170
Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
Results Highlights for Interim Results ended 30 June 2026 Revenue reached RMB1,006.5 million, increasing by 21.0% YoY Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY Gross profit margin was 34.0% HONG KONG, Aug. 26, 2026 /PRNewswire/ -- On August 26, 2026, Viva Biotech Holdings G...
2026-08-26 22:57
4095
ReviR Therapeutics Receives FDA Rare Pediatric Disease Designation for RTX-117 in Charcot-Marie-Tooth Disease
Designation supports the global development of RTX-117 and may provide potential future access to a transferable Priority Review Voucher, subject to approval and applicable requirements BRISBANE, Calif., Aug. 26, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company adv...
2026-08-26 21:00
2360
Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays
SEATTLE and RICHMOND, BC, Aug. 26, 2026 /PRNewswire/ -- Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio's proprietar...
2026-08-26 20:02
1445
SU Group Wins US$2.4 Million Follow-on Award, Expanding Landmark Smart-Hospital Project to US$13.7 Million
Additional Award Broadens the Company's Role in Mission-Critical Healthcare Infrastructure and Strengthens Revenue Visibility HONG KONG, Aug. 26, 2026 /PRNewswire/ -- SU Group Holdings Limited (Nasdaq: SUGP) ("SU Group" or the "Company"), an integrated security-related engineering services compa...
2026-08-26 20:00
2448
PENTAX Medical and MAGENTIQ EYE Expand Global Partnership to Advance AI-Assisted Colonoscopy Worldwide
Expanded agreement combines PENTAX Medical's continued investment in flexible reusable endoscopy with MAGENTIQ's clinically validated AI capabilities, expanding access to AI-assisted colonoscopy across USA, EMEA, JAPAC and LATAM. TOKYO, Aug. 26, 2026 /PRNewswire/ -- PENTAX Medical, a HOYA Group c...
2026-08-26 20:00
1618
China's BCI Race Accelerates: Gestala Raises US$84 Million in Six Months
SHANGHAI and CHENGDU, China, Aug. 26, 2026 /PRNewswire/ -- Gestala officially launched on January 1, 2026. Six months later, the company had completed two financing rounds totaling RMB 570 million, or approximately US$84 million. The financing reflects growing investor interest in alternatives t...
2026-08-26 14:36
950
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 312 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 312 media titles]
2026-08-27 10:25
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
[Picked up by 304 media titles]
2026-08-24 10:00
Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure
[Picked up by 297 media titles]
2026-08-25 10:00OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
[Picked up by 291 media titles]
2026-08-24 15:42
Most Read
LightInTheBox to Report Second Quarter 2026 Financial Results on Wednesday, August 26, 2026
2026-08-21 19:00
14875